Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Fulgent Genetics Inc's Business Segments
Fulgent Genetics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
Laboratory Services
Total Revenue
$ 70
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Laboratory Services0%
- Therapeutic Development0.1%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Laboratory Services | $ 71 | - |
| Therapeutic Development | $ 0 | 0.1% |
Revenue Share by Region - Q1 FY2026
- Other countries4.9%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Other countries | $ 3 | 4.9% |
Description of Fulgent Genetics Inc
Fulgent Genetics Inc. is a technology-based genetic testing company that offers a range of genetic testing solutions to medical professionals, researchers, and patients. It focuses on providing genetic testing services for various cancer-related and genetic diseases.
Founded in 2011 and based in Temple City, California, Fulgent Genetics Inc. offers a wide range of next-generation sequencing (NGS) and microarray products and services. These include genetic testing panels, whole-exome sequencing, carrier screening, prenatal testing, and pharmacogenetics testing.
The company's mission is to improve patient outcomes by providing high-quality, affordable genetic testing solutions that enable clinicians and researchers to make better-informed decisions for their patients. Its approach is characterized by a focus on quality, speed, and affordability of its testing services.
Fulgent Genetics Inc.'s technology platform is based on its proprietary CAP-accredited and CLIA-certified technology which has enabled the company to rapidly scale its genetic testing capabilities. It has also enabled the company to deliver accurate and reliable results at lower prices than many of its competitors.
The company's comprehensive genetic testing portfolio includes its flagship FulgentOne™ Suite of Tests, which includes more than 18,000 genes in its clinical diagnostic exome sequencing tests. This suite of tests is designed to provide physicians with a variety of options to choose from, depending on their patients' specific needs.
Fulgent Genetics Inc. has built a vast network of more than 10,000 US-based clinicians and researchers who rely on its genetic testing services. The company also has partnerships with several major healthcare providers and pharmaceutical companies.
In recent years, Fulgent Genetics Inc. has seen significant growth in its business, driven by an increase in demand for genetic testing services among healthcare professionals and consumers. In 2020, the company reported over $339 million in revenue, an increase of 542% from the previous year.
Overall, Fulgent Genetics Inc. is one of the leading genetic testing companies in the US, offering a range of high-quality and affordable genetic testing services to its clients. With its commitment to innovation and technology, the company is well-positioned to continue growing in the years to come.
Founded in 2011 and based in Temple City, California, Fulgent Genetics Inc. offers a wide range of next-generation sequencing (NGS) and microarray products and services. These include genetic testing panels, whole-exome sequencing, carrier screening, prenatal testing, and pharmacogenetics testing.
The company's mission is to improve patient outcomes by providing high-quality, affordable genetic testing solutions that enable clinicians and researchers to make better-informed decisions for their patients. Its approach is characterized by a focus on quality, speed, and affordability of its testing services.
Fulgent Genetics Inc.'s technology platform is based on its proprietary CAP-accredited and CLIA-certified technology which has enabled the company to rapidly scale its genetic testing capabilities. It has also enabled the company to deliver accurate and reliable results at lower prices than many of its competitors.
The company's comprehensive genetic testing portfolio includes its flagship FulgentOne™ Suite of Tests, which includes more than 18,000 genes in its clinical diagnostic exome sequencing tests. This suite of tests is designed to provide physicians with a variety of options to choose from, depending on their patients' specific needs.
Fulgent Genetics Inc. has built a vast network of more than 10,000 US-based clinicians and researchers who rely on its genetic testing services. The company also has partnerships with several major healthcare providers and pharmaceutical companies.
In recent years, Fulgent Genetics Inc. has seen significant growth in its business, driven by an increase in demand for genetic testing services among healthcare professionals and consumers. In 2020, the company reported over $339 million in revenue, an increase of 542% from the previous year.
Overall, Fulgent Genetics Inc. is one of the leading genetic testing companies in the US, offering a range of high-quality and affordable genetic testing services to its clients. With its commitment to innovation and technology, the company is well-positioned to continue growing in the years to come.
Fulgent Genetics Inc. specializes in genetic testing products and services that facilitate accurate and timely insights into individuals genetic makeups. The companys offerings can be extensively categorized into three primary segments: clinical testing, research testing, and COVID-19 testing.
Clinical Testing
In the clinical testing domain, Fulgent Genetics Inc. delivers a variety of genetic diagnostic services aimed at identifying inherited genetic conditions, assessing disease risk, and guiding treatment decisions. Key offerings include:
1. Carrier Screening: Fulgent Genetics provides a thorough carrier screening panel that assesses the risk of passing on more than 274 genetic conditions. This screening is crucial for couples planning to have children as it can reveal potential genetic disorders that could affect offspring.
2. Cancer Testing: The company offers a diverse selection of genetic tests that aid in assessing an individual’s susceptibility to various cancers. By identifying hereditary cancer syndromes, these tests assist healthcare providers in developing personalized treatment plans and recommend preventive measures.
3. Whole Exome Sequencing (WES): This advanced testing method examines all coding regions of an individual’s DNA, effectively detecting genetic mutations and variations that may contribute to diseases or influence treatment efficacy. WES is particularly useful when traditional testing methods cannot pinpoint a definitive diagnosis.
4. Newborn Screening: Fulgent Genetics conducts newborn screening tests designed to identify genetic conditions at birth. Early detection is vital, as some conditions can lead to serious health problems if not addressed promptly.
5. Pharmacogenomics Testing: This testing evaluates how a persons genetic makeup affects their response to medications. This can help clinicians select the most effective and safe medications, minimizing adverse drug reactions and optimizing therapeutic outcomes.
Research Testing
Fulgent Genetics also caters to research institutions and pharmaceutical companies through its research testing services. These offerings include:
1. Preclinical Studies: The company provides genetic testing services that support researchers in identifying novel drug targets and evaluating potential therapeutic strategies.
2. Clinical Trials: Fulgent Genetics plays a role in clinical trials by assisting pharmaceutical companies in the development and testing of new treatments. Genetic testing can provide vital insights into patient selection and efficacy of investigational therapies.
3. Bioinformatics Services: With the growth of genomic data, Fulgent Genetics offers bioinformatics services to facilitate the analysis and interpretation of large-scale genomic datasets. This aids researchers in deriving meaningful insights from complex genetic information.
4. Collaborative Research Projects: The company actively engages in partnerships with academic institutions and biotechnology firms to advance genetic research and the development of innovative health solutions.
COVID-19 Testing
In response to the global pandemic, Fulgent Genetics expanded its service offerings to include COVID-19 testing. Their services are designed to assist individuals and organizations in managing the public health crisis effectively. Key services include:
1. PCR Testing: Fulgent Genetics offers highly sensitive PCR tests that are the gold standard for diagnosing current COVID-19 infections. This testing is critical for guiding quarantine protocols and public health measures.
2. Antibody Testing: The company provides serological testing to determine past COVID-19 infections by detecting antibodies in the bloodstream. This service helps in assessing immunity levels and can provide valuable information for public health efforts.
3. Testing Framework for Institutions: Fulgent Genetics collaborates with organizations, schools, and corporations to establish comprehensive testing frameworks that facilitate routine screening and promote safety in various environments.
Genetic Counseling Services
In addition to the testing services, Fulgent Genetics offers genetic counseling through licensed and trained genetic counselors. These professionals assist patients in understanding their test results, implications for health and family planning, and the potential options available for disease management. Genetic counseling plays an essential role in helping individuals make informed decisions based on their unique genetic information.
Conclusion
Overall, Fulgent Genetics Inc. provides a robust array of genetic testing products and services that are essential for diagnosing and understanding genetic conditions. Their commitment to delivering precise, actionable insights equips patients, healthcare providers, and researchers with the necessary tools to enhance health outcomes and advance scientific knowledge in genetics.
Clinical Testing
In the clinical testing domain, Fulgent Genetics Inc. delivers a variety of genetic diagnostic services aimed at identifying inherited genetic conditions, assessing disease risk, and guiding treatment decisions. Key offerings include:
1. Carrier Screening: Fulgent Genetics provides a thorough carrier screening panel that assesses the risk of passing on more than 274 genetic conditions. This screening is crucial for couples planning to have children as it can reveal potential genetic disorders that could affect offspring.
2. Cancer Testing: The company offers a diverse selection of genetic tests that aid in assessing an individual’s susceptibility to various cancers. By identifying hereditary cancer syndromes, these tests assist healthcare providers in developing personalized treatment plans and recommend preventive measures.
3. Whole Exome Sequencing (WES): This advanced testing method examines all coding regions of an individual’s DNA, effectively detecting genetic mutations and variations that may contribute to diseases or influence treatment efficacy. WES is particularly useful when traditional testing methods cannot pinpoint a definitive diagnosis.
4. Newborn Screening: Fulgent Genetics conducts newborn screening tests designed to identify genetic conditions at birth. Early detection is vital, as some conditions can lead to serious health problems if not addressed promptly.
5. Pharmacogenomics Testing: This testing evaluates how a persons genetic makeup affects their response to medications. This can help clinicians select the most effective and safe medications, minimizing adverse drug reactions and optimizing therapeutic outcomes.
Research Testing
Fulgent Genetics also caters to research institutions and pharmaceutical companies through its research testing services. These offerings include:
1. Preclinical Studies: The company provides genetic testing services that support researchers in identifying novel drug targets and evaluating potential therapeutic strategies.
2. Clinical Trials: Fulgent Genetics plays a role in clinical trials by assisting pharmaceutical companies in the development and testing of new treatments. Genetic testing can provide vital insights into patient selection and efficacy of investigational therapies.
3. Bioinformatics Services: With the growth of genomic data, Fulgent Genetics offers bioinformatics services to facilitate the analysis and interpretation of large-scale genomic datasets. This aids researchers in deriving meaningful insights from complex genetic information.
4. Collaborative Research Projects: The company actively engages in partnerships with academic institutions and biotechnology firms to advance genetic research and the development of innovative health solutions.
COVID-19 Testing
In response to the global pandemic, Fulgent Genetics expanded its service offerings to include COVID-19 testing. Their services are designed to assist individuals and organizations in managing the public health crisis effectively. Key services include:
1. PCR Testing: Fulgent Genetics offers highly sensitive PCR tests that are the gold standard for diagnosing current COVID-19 infections. This testing is critical for guiding quarantine protocols and public health measures.
2. Antibody Testing: The company provides serological testing to determine past COVID-19 infections by detecting antibodies in the bloodstream. This service helps in assessing immunity levels and can provide valuable information for public health efforts.
3. Testing Framework for Institutions: Fulgent Genetics collaborates with organizations, schools, and corporations to establish comprehensive testing frameworks that facilitate routine screening and promote safety in various environments.
Genetic Counseling Services
In addition to the testing services, Fulgent Genetics offers genetic counseling through licensed and trained genetic counselors. These professionals assist patients in understanding their test results, implications for health and family planning, and the potential options available for disease management. Genetic counseling plays an essential role in helping individuals make informed decisions based on their unique genetic information.
Conclusion
Overall, Fulgent Genetics Inc. provides a robust array of genetic testing products and services that are essential for diagnosing and understanding genetic conditions. Their commitment to delivering precise, actionable insights equips patients, healthcare providers, and researchers with the necessary tools to enhance health outcomes and advance scientific knowledge in genetics.